It has been suggested that immunotherapies targeting SLAMF3 eradicate the majority of tumor cells (Figure 3) and aid in eliminating chemotherapy-resistant cells that remain in the BM following therapy in patients with MM (139). Here, LY9 is linked to neoplasm.